At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Not Yet Opened 10-20 16:08:20
5.730
-0.120
-2.05%
High6.050Low5.700Vol1.43M
Open5.850D1 Closing5.850Amplitude5.98%
Mkt Cap6.03BTradable Cap6.03BTotal Shares1.05B
T/O8.40MT/O Rate0.14%Tradable Shares1.05B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Ascletis Pharma-B Spends HK$590,300 to Repurchase 100,000 Shares on October 20
Stock News  ·  10-20 17:46
Ascletis Pharma-B Spends HK$590,300 to Repurchase 100,000 Shares on October 20
Ascletis Reports Positive Preclinical Data for Once-Weekly Oral Obesity Drug Pipeline
MT Newswires Live  ·  10-20 11:34
Ascletis Reports Positive Preclinical Data for Once-Weekly Oral Obesity Drug Pipeline
Ascletis Unveils Robust Pre-Clinical Data for Industry-Leading Once-Weekly Oral Peptide Portfolio Targeting Obesity
Bulletin Express  ·  10-20 08:20
Ascletis Unveils Robust Pre-Clinical Data for Industry-Leading Once-Weekly Oral Peptide Portfolio Targeting Obesity
Ascletis Pharma-B (01672) Reports Positive Preclinical Results for Its Most Comprehensive Once-Weekly Oral Peptide Obesity Pipeline
Stock News  ·  10-20 08:12
Ascletis Pharma-B (01672) Reports Positive Preclinical Results for Its Most Comprehensive Once-Weekly Oral Peptide Obesity Pipeline
Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
THOMSON REUTERS  ·  10-20 08:10
Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
Ascletis Accelerates Buyback: 200,000 Shares Repurchased on 16 Oct, Cumulative Tally Hits 4.45 Million
Bulletin Express  ·  10-16
Ascletis Accelerates Buyback: 200,000 Shares Repurchased on 16 Oct, Cumulative Tally Hits 4.45 Million
Ascletis Pharma Executes HKD 1.22 Million Share Buyback; Cumulative Repurchases Reach 2.75 Million Shares under 2026 Mandate
Bulletin Express  ·  10-14
Ascletis Pharma Executes HKD 1.22 Million Share Buyback; Cumulative Repurchases Reach 2.75 Million Shares under 2026 Mandate
Ascletis-B Repurchases 200,000 Shares on 13 Oct; Outstanding Buybacks Awaiting Cancellation Rise to 2.05 Million
Bulletin Express  ·  10-13
Ascletis-B Repurchases 200,000 Shares on 13 Oct; Outstanding Buybacks Awaiting Cancellation Rise to 2.05 Million
Ascletis Pharma Reports Additional Share Buyback; 200,000 Shares Repurchased on 12 Oct 2026
Bulletin Express  ·  10-12
Ascletis Pharma Reports Additional Share Buyback; 200,000 Shares Repurchased on 12 Oct 2026
Ascletis Pharma-B Repurchases 200,000 Shares for Approximately HK$1.3703 Million on October 12
Stock News  ·  10-12
Ascletis Pharma-B Repurchases 200,000 Shares for Approximately HK$1.3703 Million on October 12
Hong Kong Stock Market Movers: Innovative Drug Stocks Deepen Losses in Afternoon Session, Ascletis Pharma-B (01672) Falls Over 10%, Innovent Bio (01801) Drops Nearly 4%
Stock News  ·  10-08
Hong Kong Stock Market Movers: Innovative Drug Stocks Deepen Losses in Afternoon Session, Ascletis Pharma-B (01672) Falls Over 10%, Innovent Bio (01801) Drops Nearly 4%
ASCLETIS-B Issues 0.22 Million New Shares on Option Exercises in September, Maintains Compliant Public Float
Bulletin Express  ·  10-06
ASCLETIS-B Issues 0.22 Million New Shares on Option Exercises in September, Maintains Compliant Public Float
Ascletis Pharma Climbs Nearly 11% in Afternoon Trading as Preclinical Data for Weight-Loss Combination Therapy ASC36_35FDC Is Released
Deep News  ·  10-06
Ascletis Pharma Climbs Nearly 11% in Afternoon Trading as Preclinical Data for Weight-Loss Combination Therapy ASC36_35FDC Is Released
Hong Kong Stock Movers: Innovative Drug Stocks Extend Gains as BofA Points to Three Major Recent Partnerships Strengthening Sector Momentum and ESMO Set to Bring Dense Catalysts
Stock News  ·  10-06
Hong Kong Stock Movers: Innovative Drug Stocks Extend Gains as BofA Points to Three Major Recent Partnerships Strengthening Sector Momentum and ESMO Set to Bring Dense Catalysts
HK Movers | Innovative Drug Stocks Rally Broadly; GENSCRIPT BIO Jumps Over 6% to New High
Tiger Newspress  ·  10-06
HK Movers | Innovative Drug Stocks Rally Broadly; GENSCRIPT BIO Jumps Over 6% to New High
NIO-SW Delivers 300,301 Vehicles in First Three Quarters, Up 49.2% Year-on-Year
Stock News  ·  10-05
NIO-SW Delivers 300,301 Vehicles in First Three Quarters, Up 49.2% Year-on-Year
Ascletis Pharma Presents Preclinical Data for Weight Loss Drug at European Conference
MT Newswires Live  ·  10-02
Ascletis Pharma Presents Preclinical Data for Weight Loss Drug at European Conference
Ascletis’ ASC36_35FDC Shows Up to 24.8% Weight-Loss and Once-Quarterly Potential in Preclinical Studies
Bulletin Express  ·  10-02
Ascletis’ ASC36_35FDC Shows Up to 24.8% Weight-Loss and Once-Quarterly Potential in Preclinical Studies
Ascletis Pharma-B Reports Promising Preclinical Data for ASC36_35FDC at EASD 2026, Showing Potential for Monthly to Quarterly Dosing and Robust Weight Loss
Stock News  ·  10-02
Ascletis Pharma-B Reports Promising Preclinical Data for ASC36_35FDC at EASD 2026, Showing Potential for Monthly to Quarterly Dosing and Robust Weight Loss
Ascletis Pharma Widens H1 2026 Loss to RMB 0.32 Billion as R&D Outlays Double; Cash Pile Rises to RMB 2.31 Billion
Bulletin Express  ·  09-29
Ascletis Pharma Widens H1 2026 Loss to RMB 0.32 Billion as R&D Outlays Double; Cash Pile Rises to RMB 2.31 Billion

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--